Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Total Non-Current Liabilities (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Total Non-Current Liabilities for 7 consecutive years, with $17.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 2.29% to $17.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $17.1 million, a 2.29% decrease, with the full-year FY2025 number at $17.1 million, down 2.29% from a year prior.
  • Total Non-Current Liabilities was $17.1 million for Q4 2025 at Fulcrum Therapeutics, up from $16.3 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $34.3 million in Q2 2022 to a low of $14.0 million in Q1 2025.
  • A 5-year average of $21.6 million and a median of $21.9 million in 2023 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: increased 17.41% in 2022, then decreased 29.63% in 2025.
  • Fulcrum Therapeutics' Total Non-Current Liabilities stood at $23.5 million in 2021, then rose by 17.41% to $27.5 million in 2022, then decreased by 19.03% to $22.3 million in 2023, then decreased by 21.6% to $17.5 million in 2024, then dropped by 2.29% to $17.1 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Total Non-Current Liabilities are $17.1 million (Q4 2025), $16.3 million (Q3 2025), and $14.3 million (Q2 2025).